Comments
Sun Pharmaceutical Industries Limited has announced that the Australian Therapeutic Goods Administration (TGA) has granted regulatory approval for Winlevi, a clascoterone cream.
According to the company’s regulatory filing, Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.
Hellen de Kloet, Business Head – Western Europe, Australia, and New Zealand, Sun Pharma, said, “Winlevi is an exciting addition to our expanding dermatology portfolio of innovative medicines in Australia. Winlevi’s novel mechanism of action will be a welcome addition to the physician’s toolkit while treating acne.”
Diana Harbort, President of the Dermatology Division of Cosmo, said, “We are very pleased that Winlevi will soon be available to patients in Australia. This is another achievement in the mission of Cosmo and Sun Pharma to improve the lives of patients affected by skin conditions.”
Shares trade at ₹1,578.20 on the NSE, up by 0.44 per cent as of 9.17 a.m.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.